{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:51:09Z","timestamp":1777481469563,"version":"3.51.4"},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,12]]},"DOI":"10.18632\/oncotarget.10763","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T01:07:14Z","timestamp":1469149634000},"page":"69002-69013","source":"Crossref","is-referenced-by-count":6,"title":["A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT)"],"prefix":"10.18632","volume":"7","author":[{"given":"Ling","family":"Qi","sequence":"first","affiliation":[{"name":"Basic Medical College, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Science and Technology, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Science and Technology, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Science and Technology, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Basic Medical College, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Lv","sequence":"additional","affiliation":[{"name":"Basic Medical College, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[{"name":"Basic Medical College, Jilin Medical University, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudong","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Cardiovascular Diseases, First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,21]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/286736a0","article-title":"Glial cells in the enteric nervous system contain glial fibrillary acidic protein","volume":"286","author":"Mirsky","year":"1980","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cancergen.2012.10.009","article-title":"Genetics of adult glioma","volume":"205","author":"Jenkins","year":"2012","journal-title":"Cancer genetics"},{"key":"3","first-page":"83","article-title":"Hereditary tumor syndromes and gliomas","volume":"171","author":"von Deimling","year":"2009","journal-title":"Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Kleihues","year":"2007","journal-title":"Acta neuropathologica"},{"key":"5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ncpneuro0289","article-title":"Epidemiology and molecular pathology of glioma","volume":"2","author":"Wrensch","year":"2006","journal-title":"Nature clinical practice Neurology"},{"key":"6","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic pathways to glioblastoma: a population-based study","volume":"64","author":"Kleihues","year":"2004","journal-title":"Cancer research"},{"key":"7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/jnnp.53.6.466","article-title":"The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients","volume":"53","author":"Stefanko","year":"1990","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1227\/01.neu.0000317304.31579.17","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Pietsch","year":"2008","journal-title":"Neurosurgery"},{"key":"9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/neuonc\/nor133","article-title":"Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance","volume":"13","author":"Nimsky","year":"2011","journal-title":"Neuro-oncology"},{"key":"10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00701-013-1759-0","article-title":"Tolerance of awake surgery for glioma: a prospective European Low Grade Glioma Network multicenter study","volume":"155","author":"European Low Grade Glioma","year":"2013","journal-title":"Acta neurochirurgica"},{"key":"11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-12048-5_4","article-title":"Radiation therapy of glioblastoma","volume":"163","author":"Larson","year":"2015","journal-title":"Cancer treatment and research"},{"key":"12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"DeAngelis","year":"2013","journal-title":"Jama"},{"key":"13","first-page":"553","article-title":"A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas","volume":"26","author":"Ceroni","year":"2006","journal-title":"Anticancer research"},{"key":"14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0b013e3181bdc2e0","article-title":"Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials","volume":"15","author":"Rixe","year":"2009","journal-title":"Cancer journal"},{"key":"15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Thompson","year":"2002","journal-title":"Statistics in medicine"},{"key":"16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"Bmj"},{"key":"17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Higgins","year":"2005","journal-title":"Med Decis Making"},{"key":"18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Schwarzer","year":"2015","journal-title":"BMC medical research methodology"},{"key":"19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Weyerbrock","year":"2014","journal-title":"The Lancet Oncology"},{"key":"20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-010-0427-y","article-title":"Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial","volume":"103","author":"Kim","year":"2011","journal-title":"Journal of neuro-oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","article-title":"Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial","volume":"24","author":"Lacombe","year":"2006","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Lhermitte","year":"2015","journal-title":"Neuro-oncology"},{"key":"23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00066-008-1897-0","article-title":"Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma","volume":"184","author":"Muller","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/030089161009600110","article-title":"Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma","volume":"96","author":"Enrici","year":"2010","journal-title":"Tumori"},{"key":"25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Cloughesy","year":"2014","journal-title":"The New England journal of medicine"},{"key":"26","first-page":"1210","article-title":"Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)","volume":"44","author":"van den Bent","year":"2008","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2008.03.005","article-title":"Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors","volume":"88","author":"Schulz-Ertner","year":"2008","journal-title":"Radiother Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","article-title":"Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802","volume":"30","author":"Mehta","year":"2012","journal-title":"J Clin Onco"},{"key":"29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/ajco.12038","article-title":"Combined temozolomide and radiation as an initial treatment for anaplastic glioma","volume":"9","author":"Chua","year":"2013","journal-title":"Asia-Pacific journal of clinical oncology"},{"key":"30","first-page":"3878","article-title":"Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme","volume":"6","author":"Hess","year":"2000","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-13-299","article-title":"Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial","volume":"13","author":"de-Castro","year":"2013","journal-title":"BMC cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Lacombe","year":"2005","journal-title":"The New England journal of medicine"},{"key":"33","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ncponc1155","article-title":"Mechanisms of disease: temozolomide and glioblastoma\u2014look to the future","volume":"5","author":"Chamberlain","year":"2008","journal-title":"Nature clinical practice Oncology"},{"key":"34","first-page":"3","article-title":"Nimustine Induces DNA Breaks and Crosslinks in NIH\/3T3 Cells","author":"Zhong","year":"2013","journal-title":"International Journal of Bioscience Biochemistry & Bioinformatics"},{"key":"35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijbiomac.2015.09.024","article-title":"SERS as an advanced tool for investigating chloroethyl nitrosourea derivatives complexation with DNA","volume":"81","author":"Mehrotra","year":"2015","journal-title":"International journal of biological macromolecules"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Goth, Rajewsky. Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. Proceedings of the National Academy of Sciences of the United States of America. 1974; 71:pp. 639\u2013643.","DOI":"10.1073\/pnas.71.3.639"},{"key":"37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-7992(90)90094-Z","article-title":"DNA repair and chromosomal stability in the alkylating agent-hypersensitive Chinese hamster cell line 27-1","volume":"243","author":"Natarajan","year":"1990","journal-title":"Mutation research"},{"key":"38","doi-asserted-by":"crossref","first-page":"543531","DOI":"10.4061\/2010\/543531","article-title":"DNA damage induced by alkylating agents and repair pathways","volume":"2010","author":"Ohnishi","year":"2010","journal-title":"Journal of nucleic acids"},{"key":"39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.onc.1209785","article-title":"Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine","volume":"26","author":"Kaina","year":"2007","journal-title":"Oncogene"},{"key":"40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0968-0004(00)89095-7","article-title":"Cisplatin and DNA repair in cancer chemotherapy","volume":"20","author":"Lippard","year":"1995","journal-title":"Trends in biochemical sciences"},{"key":"41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/15216540701636287","article-title":"Understanding cisplatin resistance using cellular models","volume":"59","author":"Davey","year":"2007","journal-title":"IUBMB life"},{"key":"42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Lippard","year":"2005","journal-title":"Nature reviews Drug discovery"},{"key":"43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1600-0773.1995.tb00167.x","article-title":"Mechanism of cisplatin ototoxicity: antioxidant system","volume":"76","author":"Rybak","year":"1995","journal-title":"Pharmacology & toxicology"},{"key":"44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","article-title":"Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer","volume":"12","author":"Voest","year":"2007","journal-title":"The oncologist"},{"key":"45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3174\/ajnr.A1987","article-title":"Bevacizumab (Avastin)","volume":"31","author":"Mukherji","year":"2010","journal-title":"AJNR American journal of neuroradiology"},{"key":"46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Wen","year":"2008","journal-title":"Neurology"},{"key":"47","first-page":"285","article-title":"Bevacizumab for malignant gliomas","volume":"67","author":"Fine","year":"2010","journal-title":"Archives of neurology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:11:06Z","timestamp":1718709066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,21]]},"references-count":47,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2016,10,12]]}},"alternative-id":["10763","27458167"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10763","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,21]]}}}